These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33191315)

  • 1. Apolipoprotein A2 Isoforms: New Insight into the Risk of Myocardial Infarction.
    Hisamatsu T
    J Atheroscler Thromb; 2021 May; 28(5):469-470. PubMed ID: 33191315
    [No Abstract]   [Full Text] [Related]  

  • 2. Apolipoprotein A2 Isoforms in Relation to the Risk of Myocardial Infarction: A Nested Case-Control Analysis in the JPHC Study.
    Kihara T; Yamagishi K; Honda K; Ikeda A; Yatsuya H; Saito I; Kokubo Y; Yamaji T; Shimazu T; Sawada N; Iwasaki M; Iso H; Tsugane S;
    J Atheroscler Thromb; 2021 May; 28(5):483-490. PubMed ID: 32863295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein-mediated cellular cholesterol efflux.
    Yokoyama S
    Biochim Biophys Acta; 1998 May; 1392(1):1-15. PubMed ID: 9593801
    [No Abstract]   [Full Text] [Related]  

  • 4. The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?
    Heinecke JW
    Nat Med; 2012 Sep; 18(9):1346-7. PubMed ID: 22961165
    [No Abstract]   [Full Text] [Related]  

  • 5. To be Functional, or not to be Low in Cholesterol, that is the Clinical Concern when Evaluating Anti-Atherosclerotic Actions of High-Density Lipoproteins.
    Yoshida H
    J Atheroscler Thromb; 2021 Jul; 28(7):694-695. PubMed ID: 34024874
    [No Abstract]   [Full Text] [Related]  

  • 6. Apolipoprotein A-II accelerates reactive AA amyloidosis.
    Yang M; Liu Y; Li L; Miyahara H; Ding X; Dai J; Sawashita J; Mori M; Higuchi K
    Amyloid; 2017 Mar; 24(sup1):147-148. PubMed ID: 28434311
    [No Abstract]   [Full Text] [Related]  

  • 7. Apolipoprotein A-II modulates HDL remodeling in plasma.
    Calabresi L; Banfi C; Sirtori CR; Franceschini G
    Biochim Biophys Acta; 1992 Mar; 1124(2):195-8. PubMed ID: 1543740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoA-II versus ApoA-I: two for one is not always a good deal.
    Castellani LW; Lusis AJ
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1870-2. PubMed ID: 11742857
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids.
    Gao D; Podrez EA
    Free Radic Biol Med; 2018 Feb; 115():57-67. PubMed ID: 29155052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial fluid apolipoprotein A-II: an association with the occurrence of myocardial infarction.
    Luc G; Majd Z; Poulain P; Elkhalil L; Fruchart JC
    Atherosclerosis; 1996 Nov; 127(1):131-7. PubMed ID: 9006813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux.
    Bernini F; Calabresi L; Bonfadini G; Franceschini G
    Biochim Biophys Acta; 1996 Jan; 1299(1):103-9. PubMed ID: 8555242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-linked glycosylation modifies the association of apolipoprotein A-II to high density lipoproteins.
    Remaley AT; Wong AW; Schumacher UK; Meng MS; Brewer HB; Hoeg JM
    J Biol Chem; 1993 Mar; 268(9):6785-90. PubMed ID: 8454651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-density lipoprotein and atherosclerosis: the role of antioxidant activity.
    Bandeali S; Farmer J
    Curr Atheroscler Rep; 2012 Apr; 14(2):101-7. PubMed ID: 22441969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human apolipoprotein A-II protects against diet-induced atherosclerosis in transgenic rabbits.
    Wang Y; Niimi M; Nishijima K; Waqar AB; Yu Y; Koike T; Kitajima S; Liu E; Inoue T; Kohashi M; Keyamura Y; Yoshikawa T; Zhang J; Ma L; Zha X; Watanabe T; Asada Y; Chen YE; Fan J
    Arterioscler Thromb Vasc Biol; 2013 Feb; 33(2):224-31. PubMed ID: 23241412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency.
    van Capelleveen JC; Kootte RS; Hovingh GK; Bochem AE
    J Clin Lipidol; 2015; 9(3):396-9. PubMed ID: 26073400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity.
    Vergès B; Adiels M; Boren J; Barrett PH; Watts GF; Chan D; Duvillard L; Söderlund S; Matikainen N; Kahri J; Lundbom N; Lundbom J; Hakkarainen A; Aho S; Simoneau-Robin I; Taskinen MR
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1398-406. PubMed ID: 26835543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Remodelling of high density lipoproteins by plasma factors.
    Rye KA; Clay MA; Barter PJ
    Atherosclerosis; 1999 Aug; 145(2):227-38. PubMed ID: 10488948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-density lipoprotein synthesis and metabolism (Review).
    Zhou L; Li C; Gao L; Wang A
    Mol Med Rep; 2015 Sep; 12(3):4015-4021. PubMed ID: 26082200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.
    Castellani LW; Navab M; Van Lenten BJ; Hedrick CC; Hama SY; Goto AM; Fogelman AM; Lusis AJ
    J Clin Invest; 1997 Jul; 100(2):464-74. PubMed ID: 9218525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.